Dissecting PTPN7‐driven aggressiveness in IDH‐wildtype astrocytomas: multi‐omics, clinical validation, and spatial transcriptomics for prognostic insights
This study positions PTPN7 as a prognostic biomarker and immune modulator in gliomas, particularly IDH-wildtype astrocytomas. Its expression correlates with tumor aggressiveness and immune infiltration, potentially driving glioma progression. Targeting PTPN7 may disrupt immune evasion and support tumor eradication, indicating a promising therapeutic avenue in immunotherapy-based strategies.
Authors
- Dueng‐Yuan Hueng (ORCID: https://orcid.org/0000-0001-7868-3161)
- Yao‐Feng Li (ORCID: https://orcid.org/0000-0001-9601-8149)
- Tung Liu
- Pei-Chi Chang
- Yu‐Chieh Lin
Institutions
- Tri-Service General Hospital (TW)
- Taoyuan Armed Forces General Hospital (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1007/s12672-025-02662-5
- Citations
- 2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- Academia Sinica
- Tri-Service General Hospital
- Kaohsiung Veterans General Hospital
- National Science and Technology Council
- Medical Affairs Bureau